4basebio (LON:4BB) Insider Acquires £15,529 in Stock

4basebio PLC (LON:4BB) insider Amy Walker bought 2,650 shares of 4basebio stock in a transaction dated Friday, February 13th. The shares were acquired at an average cost of GBX 586 per share, with a total value of £15,529.

4basebio Price Performance

4basebio stock opened at GBX 580 on Thursday. The stock has a market capitalization of £89.81 million, a P/E ratio of -5.86 and a beta of 1.09. The company’s fifty day moving average price is GBX 593.23 and its 200 day moving average price is GBX 724.02. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73. 4basebio PLC has a 1 year low of GBX 520 and a 1 year high of GBX 1,220.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.